Aim: The purpose of this review is to summarize and evaluate the current status of clinical research on the use of Chinese herbal medicine in treating cancer pain, with emphasis on the efficacy and safety of the applications. Method: A search of the clinical research published between 1986 and 2006 on the effects and applications of Chinese herbal medicine in cancer pain management was conducted using databases of CBM, CMCC, Wanfang, and Weipu (available since 1989) in Chinese and PubMed and EMBASE in English. We included only reports of original publications on cancer-induced pain, resulting in a total of 115 articles. We evaluated the methodological quality of the articles following the guidelines set forth as "Levels of Evidence of Human Studies of Cancer in Complementary and Alternative Medicine" by the National Cancer Institute. Results: Various methods of traditional Chinese medicine herbal treatment for cancer pain management have been reported. These methods include external application, oral administration, intravenous infusion, and other applications such as inhalation and clysmata. Forty-one of the 115 studies reviewed were randomized controlled clinical trials, most comparing the effects of Chinese herbal medicine to conventional analgesics and the others using placebo controls. These trials suggest that (1) Chinese medicine may be effective for cancer pain, and its effects are similar to those of Western analgesics; (2) Chinese medicine may reduce the side effects of conventional analgesics, thus enhancing cancer patients' quality of life; and (3) the various methods of application-topical, oral, and intravenous-are suitable to treat a range of pain conditions found in cancer patients. However, trials were of varying quality with respect to control group selection, dosing and side effect information, and outcome measures. Conclusion: The studies reviewed in this article suggest that Chinese herbal medicine may be useful for managing cancer pain, at least for short-term application. The products evaluated appear relatively safe, with no serious adverse effects reported. However, the quality of the published reports is variable. More research using rigorously controlled clinical trial design is warranted.
The International Association for the Study of Pain defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Pain management improves the patient's quality of life throughout all stages of disease. The World Health Organization (WHO) has described a 3-step analgesic ladder as a framework for pain management (Figure 1 ). It involves a stepped approach based on the severity of pain. For mild pain, one may begin by prescribing a step 1 analgesic such as acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). If pain persists or worsens despite appropriate dosage increase, a change to a step 2 or step 3 analgesic is indicated. Opioids are the major class of analgesics used in management of moderate to severe pain. 1 NSAIDs and opioids represent the mainstay for the management of chronic cancer pain. However, NSAID and opioid treatments are limited by their adverse effects. Potential adverse effects of NSAIDs include gastric ulceration, hepatic dysfunction, myocardial infarction, and renal failure. [2] [3] [4] [5] Common adverse effects of opioids are nausea, somnolence, and constipation. 6 Long-term opioid therapy may result in tolerance and decreased efficacy of pain control, requiring therapy adjustments and additional interventions. 6 Complementary and Alternative Medicine (CAM) has been used to fulfill patient needs in lieu of or as an adjunct to conventional medicine. 7 More than half of CAM patients reported effective relief of their symptoms including pain. 8 Herbs have received increasing public interest, accounting for $5.1 billion in sales among US consumers alone in 1997. It is reported that 41% to 62% of cancer patients use herbs as a complementary or alternative medical therapy. 9, 10 Clinical observation suggests that herbal medicine may alleviate cancer pain with no adverse effects, but the scientific evaluation of efficacy of herbs on pain is lacking, the underlying mechanisms are unclear, and safety and toxicity are concerns.
There is a lack in particular of reviews and evaluations of the literature published in Chinese on the safety and efficacy of Chinese herbal preparations for the treatment of cancer pain. This review aims to provide much needed information on this topic for the English-speaking medical community.
According to traditional Chinese medicine (TCM) philosophy, the human body must be perceived and treated as a whole. Health is the result of harmony among bodily functions and between the body and nature, and disease occurs when this harmony is disrupted. TCM interventions are used to restore the state of harmony. A vital energy known as qi flows through meridians and participates in the homeostatic regulation of various bodily functions. When the normal flow of energy over a meridian is obstructed (eg, as a result of tissue injury or a tumor), pain or other symptoms result.
Cancer pain is referred to as topical pain caused by the tumor invasion of a meridian or qi and blood flow blocking the meridian. Although the pathogenesis of cancer pain is complicated, it can be summarized in 2 aspects. The first aspect is that the pain may be induced by stagnation of qi and blood. The second aspect is that the pain may result from insufficiency of qi and blood flow. Thus, the main therapeutic goals of TCM are to promote and replenish qi and blood, to activate blood, to soften hard lumps and dispel nodes, and to warm the meridian. The methods of management of cancer pain with Chinese medicine vary according to the character of the pain. 11 Various methods of TCM herbal treatment for cancer pain management have been reported. These methods include external application, oral administration, intravenous infusion, and other applications such as inhalation and clysmata. 11 1. External treatment of cancer pain has been most commonly reported in the literature. External treatment is often used for patients who cannot take oral administration (eg, those with nausea and vomiting) or whose pain has a specific location (eg, low back). External treatments include plaster, pulvis, or tincture applied at the pain site or the use of iontophoresis at an acupuncture point. Making sticking plaster is a 3-step process: 12 (1) the herbal preparation is decocted into an extractum or ground to fine powder;
(2) the extractum or fine powder is mixed with sufficient base materials, such as rice wine, alcohol, oil of turpentine, egg albumin, honey, or water; and (3) the commixture is agitated into the paste. A tincture is a liquid extract of herbs. Tinctures are made by soaking herbs in menstruum (solvent) such as alcohol or glycerin. The menstruum extracts the chemical constituents of the herbs. The herb material is then removed from the menstruum, usually after several weeks of incubation, once the medicinal properties of the herbs have been extracted into the alcohol.
Oral administration includes decoctions or extracts
formed into capsules or tablets and is often used for patients with visceral pain.
Intravenous administration includes purified extracts
of Chinese herbs, often made by pharmaceutical companies that are used in intravenous infusions for patients with visceral or somatic pain. 4. Other applications include materials for inhalation or clysmata, which are usually made by pharmaceutical companies that are commonly used in cases of solid tumors such as nasopharyngeal carcinoma, carcinoma of the maxillary sinus, lung cancer, and gastric carcinomas. [13] [14] [15] 
Examples of Chinese Medicine Preparations Used for Pain Management
Three major kinds of Chinese medicine are usually used to control pain (see Tables 1 and 2) : 18 Tong-shu-gao Diplopod (Malu 马陆); Radix Aconiti (Chuanwu 川乌); Radix Aconiti Kusnezoffii (Caowu 草乌); Giant typhonium herb (Dujiaolian 独角莲); Semen Strychni (Maqianzi 马钱子); Radix Sophorae Flavescentis (Kushen 苦参); Spina Gleditsiae (Zaojiaoci 皂角刺) Liu et al (2006) 19 Chinese medicine Dragon's blood (Xuejie 血竭); Libanotus (Ruxiang 乳香); Myrrha (Moyao 没药); tincture Borneolum Syntheticum (Bingpian 冰片) He (2005) 20 Zhong-yao-zhi-tong Pericarpium Papaveris (Yingsuqiao 罂粟壳); Corydalis rhizoma (Yanhusuo 延胡索); plaster Paeoniae rubra radix (Chishao 赤芍); Paeoniae alba radix (Baishao 白芍); Carthami flos (Honghua 红花); Rhizoma Curcumae (Ezhu 莪术); Semen Coicis (Yiyiren 薏苡仁) Yuan et al (2005) 21 Ai 27 Compound Chanshu Venenum Bufonis (Chansu 蟾酥); Moschus (Shexiang 麝香); Broneolum Powder Syntheticum (Bingpian 冰片); Cortex Cinnamomi (Rougui 肉桂); Herba Asari (Xixin 细辛); Radix Aconiti Kusnezoffii (Caowu 草乌); dragon's blood (Xuejie 血竭); Semen Persicae (Taoren 桃仁); Rhizoma Sparganii (Sanleng 三棱); Rhizoma Curcumae (Ezhu 莪术); Indigo Naturalis (Qingdai 青黛); Herba Lycopi (Zelan 泽兰); Cortex Phellodendri (Huangbo 黄柏); Radix Rubiae (Qiancao 茜草) Kou et al (2003) 28 Yuan-she-zhi-tong Corydalis Rhizoma (Yanhusuo 延胡索); Moschus (Shexiang 麝香); Venenum Bufonis physic liquor (Chansu 蟾酥); Calculus Bovis (Niuhuang 牛黄); Broneolum Syntheticum (Bingpian 冰片)
Yang and Chen
Zhong-yao-tu-bu-ji Radix Aconiti (Chuanwu 川乌); Dried toad skin (Ganchanpi 干蟾皮); Caulis (2003) 29 transdermal plaster Spatholobi (Jixueteng 鸡血藤); Rhizoma Curcumae (Ezhu 莪术); Rhizoma Typhonii (Baifuzi 白附子); Flos Caryophylli (Dingxiang 丁香) Jia et al (2002) 30 Hua- 64 Ai-Tong-Ning pill Corydalis rhizoma (Yanhusuo 延胡索); etc Chen (2004) 65 Shi 66 Tian chan capsule Rhizoma Corydalis Decumbentis (Xiatianwu 夏天无); Radix Aconiti (Chuanwu 川乌); Venenum Bufonis (Chansu 蟾酥); Giraldi daphne (Zusima 祖司麻); Radix Angelicae Dahuricae (Baizhi 白芷); Paeoniae alba radix (Baishao 白芍); Chelidonii herba (Baiqucai 白屈菜); Radix Gentianae Macrophyllae (Qinjiao 秦艽); Ligusticum rhizoma (Chuanxiong 大黄); Radix Glycyrrhizae (Gancao 附子) Ma et al (2003) 67 Jia-Wei-Bao-An-Ke-Li Radix et Rhizoma Rhei (Dahuang 大黄); Radix Aconiti Lateralis Preparata (Fuzi 附子); Carapax Trionycis (Biejia 鳖甲); Rhizoma Arisaematis (Tiannanxing 天南星); Paeoniae alba radix (Baishao 白芍); Radix Glycyrrhizae (Gancao 甘草) Li et al (2002) 68 Lamiophlomis rotata Lamiophlomis rotata Kudo (Duyiwei 独一味) Kudo capsule Zhang (2001) 69 Compound Semen Strychni (Maqianzi马钱子); Radix Glycyrrhizae (Gancao 甘草) Strychnos Capsule Lin et al (2001) 70 Jia - The purpose of this review is to summarize and evaluate the current status of clinical research on the use of Chinese herbal medicine in treating cancer pain, with emphasis on the efficacy and safety of the applications published in the Chinese medical and scientific literature. The methodological challenges of designing and conducting adequate clinical trials will also be discussed.
Methods
A search of the clinical research published from 1986 to 2006 on the effects, mechanisms, and applications of Chinese herbal medicine in cancer pain management was conducted using databases in English and Chinese. These comprise CBM, CMCC, Wanfang, and Weipu (available since 1989) in Chinese and PubMed and EMBASE in English. The keywords in Chinese were "癌症" (cancer), "肿瘤" (tumor), "中药" (Chinese medicine), "中草药" (Chinese herbal medicine),"中西医结合" (integrative Chinese and Western medicine), and "疼痛" (pain). The Chinese search strategy was "中药" and "癌症" and "疼痛", "中药" and "肿 瘤" and "疼痛", "中草药" and "癌症" and "疼痛", "中 草药" and "肿瘤" and "疼痛", "中西医结合" and "癌 症" and "疼痛", and "中西医结合" and "肿瘤" and "疼痛". The English search strategy in EMBASE was (Chinese herb/exp OR Chinese medicine/exp) AND neoplasms/exp AND pain/exp. The English search strategy in PubMed is shown in Table 3 . The search yielded 212 articles in Chinese databases and 161 English items in English databases. We include only reports of original works on cancer-induced pain, bringing the total to 115 articles, including 106 articles in Chinese and 9 articles in English (8 in Chinese journals and 1 in BJU International). We excluded reviews, commentaries, conference abstracts, individual case reports, and reports on treatment for pain associated with cancer therapies such as chemotherapy, radiotherapy, or surgery ( Figure 2 ). We evaluated the methodological quality of the articles following the guidelines set forth as "Levels of Evidence of Human Studies of Cancer in Complementary and Alternative Medicine" by the National Cancer Institute (NCI) (http://www.cancer.gov/cancertopics/pdq/levelsevidence-cam/HealthProfessional/page2). These studies were categorized into randomized controlled clinical trials (RCTs), nonrandomized controlled clinical trials (NRCTs), population-based consecutive case series, nonconsecutive case series, and best cases series ( Table 4 ).
Results

External Application
External application is the most common way that Chinese medicine is used in cancer pain. Forty-one human studies evaluated the effects of externally applied Chinese remedies on cancer pain. Among them, 14 were RCTs 18-31 (see Table 5 ), 5 were NRCTs, [32] [33] [34] [35] [36] 16 were population-based consecutive case series, 37-52 2 were nonconsecutive case series, 53,54 and 4 were best cases. [55] [56] [57] [58] Chen et al 31 conducted an RCT (n = 250) comparing the effect of an external herbal product, Kang-Fu-Zhi-Tong adhesive plaster (n = 182, 30 g/d), to that of morphine (n = 68, 10 mg every 10 minutes) in patients with cancer pain. The investigators reported that 108 Polygoni Multiflori (Heshouwu 何首乌) Jin et al (2004) 110 Wang and Sun (2004) 112 Luo et al (2003) 113 Zeng et al (2003) 114 An and Wang (2003) 115 Liu et al (2005) 109 Hua-Chan-Su injection Venenum Bufonis (Chansu 蟾酥) Shi et al (2002) 116 Ma (2004) 111 Shen-Fu injection Radix Ginseng Rubra (Hongshen 红参); Radix Aconiti Lateralis Preparata (Fuzi 附子) Wang et al (2002) 117 Kang-Lai-Te injection Semen Coicis (Yiyiren 薏苡仁) Luo and Kong (2001) 118 the analgesic effect was equivalent in the 2 groups after 3 days of treatment (P > .05). However, the data showed that analgesia was prolonged significantly in the herbal treatment group compared with the morphine control group, whereas the onset of analgesia was slower in the herbal group (P < .01). Ji et al 24 reported an RCT in which 46 liver cancer patients were divided into 2 groups, 26 patients treated with an external Chinese herbal product, She-Bin-Zhi-Tong transdermal plaster, once every 8 hours for 7 days, and 20 in a control group given a conventional analgesic, tramadol, 100 mg every 12 hours for 7 days. Total pain relief was equivalent in the 2 groups, with 88.5% in the herbal treatment group and 90% in the control group (P > .05). However, analgesic onset in the herbal treatment group took 0.43 ± 0.51 hours, whereas in the control group, it took 1.39 ± 0.26 hours (P < .01).
Ten of the 14 RCTs 18,21-26,28,30,31 used positive controls, known conventional analgesics such as morphine (an opioid), Duragesic (an anesthetic), bucinperazine and Tramal (tramadol) (analgesics), or Voltaren emulsion (an NSAID). Three of the 14 RCTs 19,20,32 compared White peony Alba (Raidix Paeoniae Alba; Anti-inflammatory, analgesic 192, 193 Total glycosides, tannin, triterpenes, Baishao 白芍) flavanoid, polycose 192, 193 a Chinese medicine/radiotherapy combination to a radiotherapy regimen alone. The other 2 studies 27,29 compared a commercial Chinese herbal preparation, Chan-Shu plaster. In all of these studies, the analgesic effects of the Chinese herbal medicine and the positive controls were equivalent. Chinese herbal therapy combined with analgesics or radiotherapy was better than analgesics or radiotherapy alone. Five NRCTs on external Chinese herbal applications were identified. Zhao et al 32 compared a Chinese herbal product, Shu-Luo-Gao transdermal plaster (n = 80), to an analgesic drug, pethidine (n = 80), on patients with severe cancer pain. The plaster was applied at acupuncture points for 2 to 4 hours. Pethidine was delivered as a 100-mg intramuscular injection, as needed. The rate of pain relief was similar in the 2 groups: 88.75% pain reduction in the herbal group and 92.50% in the control group (P > .05). However, the onset of analgesia was significantly faster (P < .01) in the drug group (1 hour) than in the herbal group (4 hours), whereas analgesic duration was significantly longer (P < .01) in the herbal group (4-72 hours) than in the drug group (4-24 hours).
Xu et al
In a study reported by Zhou, 33 patients with cancer pain were assigned to either a topical herbal treatment group (Ai-Tong-Lin spray, n = 150) or a control group receiving an analgesic drug, Hao-De-Kuai aerosol (lidocaine and chlorhexine acetate aerosol, n = 50). The substances were sprayed on the pain site, 0.5 mL/cm 2 , 4 times daily. After 7 days of treatment, pain alleviation was significantly greater in the herbal group than in the control group (P < .01). Cancer Pain relief ranged from 40% to 95% in the treatment group, which was made up of patients with various types of cancer. The other 3 NRCTs 34-36 also used positive controls, such as pethidine, Tramal, and chemotherapy (5-FU). The pain relief in the treatment group ranged from 77.3% to 96.7%, whereas that in the control group ranged from 57.1% to 77.27%.
Chinese Herbal Medicine for Cancer Pain
Sixteen population-based, consecutive case series on external herbal applications were reported. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] In these studies, pain relief from the herbal applications reportedly ranged between 63.33% and 95.8%; analgesic duration, between 1 and 9 hours; and onset of analgesic action, between 15 minutes and 4 hours. Two nonconsecutive case series 53,54 and 4 best cases reported similar results. [55] [56] [57] [58] 
Oral Administration
Forty-eight studies on Chinese herbal medicine orally administered for cancer pain were reviewed. Among them, 14 were RCTs 59-72 (see Table 6 ) that compared an herbal treatment group with a standard practice (3-step analgesic ladder) group. Eight were NRCTs, 73-80 12 were population-based consecutive case series, 81-92 7 were nonconsecutive case series, [93] [94] [95] [96] [97] [98] [99] and 7 were best cases series. [100] [101] [102] [103] [104] [105] [106] Xu et al (3) Tx: constipation (3), dizziness (2), nausea (5) , somnolence (2); Ctr: stomach upset (2), constipation (11), dizziness (2), nausea (7), somnolence (5) ; I = patient feels mild, tolerable pain; sleep is good, movement is unrestricted, facial expression is good; II = patient feels moderate, tolerable pain; sleep is poor because of pain, movement is limited, facial expression shows pain; III = patient feels severe, intolerable pain and cannot sleep because of pain; movement is limited, facial expression shows pain, and patient groans constantly; CR = complete relief; PR = partial relief; MR = moderate relief; AR = apparent relief; NR = no relief; q = every; IV = intravenously; NRS = numerical rating scale; VAS, visual analog scale; PO., orally; WHO, World Health Organization; NRCT, nonrandomized controlled trial. Chen et al 71 reported a double-blind multicenter RCT that examined the efficacy and safety of a Chinese herbal analgesic mixture, Gui-Shen, for treating cancer pain (N = 418). Patients were randomly assigned to 1 of 3 groups. The experimental group (n = 204) received Gui-Shen (50 mL) plus a placebo drug (2 tablets) every 8 hours. The control group (n = 114) was given an analgesic drug, bucinperazine (60 mg), plus a placebo herbal mixture every 8 hours. The third group was an unblinded group (n = 100) in which patients were given Gui-Shen (50 mL) alone every 8 hours. Pain was evaluated using a numerical scale of 0 to 10, where 0 equals no pain and 10 equals the worst pain imaginable. After 7 days of treatment, the effective rate of the Gui-Shen was 73.53% in treating moderate cancer pain, the control group rate was 69.30%, and the unblinded group rate was 71%. There was no significant difference among the 3 groups in terms of the rate of pain relief, the onset of analgesic action, analgesic duration, or adverse reactions.
Wu et al 63 reported an RCT evaluating mechanisms and therapeutic effects of an encapsulated Chinese herbal product, Ai-Tong-Ping, on cancer pain. Sixty cancer patients were randomly assigned to 2 groups, a treatment group (n = 30) that received Ai-Tong-Ping (1.6 g) and a control group (n = 30) receiving diclofenac, an analgesic, 40 mg orally 3 times a day for 1 week. Outcome measurements, consisting of pain, plasma β-endorphin (β-EP) and cyclic adenosine monophosphate (cAMP) levels, hemorheologic index, life quality, and adverse reactions (nausea, vomiting, and constipation), were evaluated at baseline and at the end of the treatment. The treatment group scored significantly better in degree of pain relief, increase of plasma β-EP, decrease of cAMP, quality of life, and hemorheologic index and had reduced incidences of adverse reactions (P < .05 or P < .01).
Wei et al 66 presented a randomized, double-blind, multicenter, prospective trial on the efficacy and safety of Tian-Chan in the treatment of medium cancer pain. Two hundred patients were randomly assigned to 2 groups. The treatment group (n = 100) received Tian-Chan (3 capsules) plus a placebo drug (1 tablet) 3 times a day for 5 days. The control group was given an opioid, paracetamol codeine phosphate (1 tablet), plus a placebo drug (3 tablets) orally 3 times a day for 5 days. The total effective rate of Tian-Chan was 83% versus 85% for the control group (P > .05). Mean onset of analgesic action was 2.08 ± 2.82 hours for the treatment group and 2.13 ± 1.41 hours for control. The main side effects of Tian-Chan were nausea and vomiting.
Lin et al 61 observed the short-term efficacy and safety of a Shen-Qi mixture combined with microwave coagulation in treating primary hepatocellular carcinoma. Seventy-two patients were randomly assigned to 2 groups, treatment and control, with 36 in each. Microwave therapy was applied to both groups by double leads, 60 W, 800 seconds once a week for 2 weeks. To the treated group, the Shen-Qi mixture was given additionally through oral intake of 20 mL, 3 times a day for 1 month. The results showed that the effective rate of pain control in the treated group was significantly higher than that in the control group (80.76% vs 36.36%, P < .01).
Similar results were reported in the other 10 RCTs 59, 60, 62, 64, 65, [67] [68] [69] [70] 72 that compared Chinese oral herbal medicines with analgesic drugs such as codeine, bucinperazine, Tramal, paracetamol, and indomethacin. These studies showed the Chinese herbs to have analgesic effects equivalent to those of the positive controls, with total rate of pain relief ranging from 71% to 96.67% versus 52% to 97.5% in controls. Average onset of analgesia ranged from 17.26 minutes to 2.9 hours versus 16.67 minutes to 3.58 hours in controls. Analgesic duration ranged from 3.66 to 7.8 hours versus 3.83 to 6.6 hours in controls. Three RCTs 59,62,70 compared a Chinese herbal medicine/analgesic drug combination with an analgesic drug control. These 3 studies indicated that the analgesic effects in the combination treatment groups were significantly better than those in the control group (P < .05 62, 70 and P < .01 59 ), and the combination groups had fewer side effects (P < .05).
Two NRCTs 73,74 (see Table 6 ) compared a Chinese medicine/chemotherapy combination with chemotherapy alone for 2 months. The chemotherapy regimen was designed to treat the primary cancer. Both studies showed that analgesia was significantly better in the trial group than in the control group (P < .05). Similar results were reported by another 4 NRCTs. [75] [76] [77] [78] Two NRCTs 79,80 compared Chinese medicine/supportive care with supportive care alone. Both studies showed that pain control was significantly better in the trial group than in the control group (P < .05).
A population-based, consecutive case series 81 presented the therapeutic effect of a Xian-Long-Ding-Tong decoction on pain caused by metastasized bone cancer. Thirty-two patients with bone metastasis received 200 mL of Xian-Long-Ding-Tong twice a day for 15 days. Therapeutic and adverse effects were observed on the 3rd, 7th, and 15th days, and quality of life was evaluated using the Karnofsky criteria. The total effective rates were 71.88%, 78.13%, and 84.38% on the 3rd, 7th, and 15th days, respectively; the Karnofsky score before and after treatment was 48.3 ± 38.33 versus 68.28 ± 12.56 (P < .01). No adverse reactions were detected.
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A prospective clinical trial 82 evaluated the possible toxic and beneficial effects of PC-SPES. After hormoneablative therapy had failed, and with established disease progression, 16 patients received supplemental treatment with PC-SPES (2.88 g daily) for 5 months. Hormonal therapy was continued throughout the trial to avoid the known withdrawal effect of antiandrogen on prostate-specific antigen (PSA) levels. The supplemental intake of PC-SPES was associated with significant (P < .05-.01) improvements in qualityof-life measures, reductions in patients' pain ratings (P < .05-.01), and a decline in PSA levels (P < .01), with no major side effects.
The other 10 population-based, consecutive case series, 83-92 7 nonconsecutive case series, 93-99 and 7 best cases series [100] [101] [102] [103] [104] [105] [106] reported the analgesic effect of Chinese medicine decoctions or capsules. In all of these, the Chinese medicine reduced pain intensity in patients with cancer pain.
Intravenous Infusions
During the past several decades, intravenous infusions of Chinese medicine have been developed by herbal pharmaceutical companies. These products are used not only for cancer symptom management, such as for cancer pain and patient quality of life, but also for antitumor treatment. Twenty-three studies evaluating such infusions have been reported. Twelve were RCTs 107-118 (see Table 7 ), 10 were populationbased consecutive case series, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] and 1 was a best case. 129 Liu et al 109 reported on 60 patients with terminal cancer randomly assigned to 2 groups. A treatment group (n = 30) was treated with intravenous injections (30 mL once daily for 28 days) of Hua-Chan-Su. A control group (n = 30) was managed with morphine (10 or 30 mg every 12 hours for 28 days). Pain was assessed using a verbal rating scale. Quality of life was evaluated using the Karnofsky criteria. The authors reported that the rates of pain relief in the treatment group and the control group were equivalent (80.95% vs 73.91%; P > .05), but quality of life was higher in the treatment group (86.7% vs 63.3%; P < .01). In the treatment group, 1 patient reported a fever that may have been associated with the herbal product, and 2 reported skin reactions at the injection site. In the control group, 2 patients reported nausea and vomiting, and 5 reported constipation.
Shi et al 116 reported an RCT in which 32 cancer pain patients were divided into a treatment (n = 17) and a control group (n = 15). The treatment group received bilateral intramuscular injections of the herbal product Hua-Chan-Su at acupuncture point St-36 (Zusanli), 1 mL each side every other day for 10 days. The control group was injected with 0.9% saline at the same point according to the same treatment protocol. The data showed that analgesia was better in the treatment group than in the control group: respective pain relief rates were 64.70% and 33.33%. Mean onset of analgesia was 20.62 ± 7.15 minutes in the treatment group versus 31.42 ± 8.06 minutes in the control group. Respective analgesic durations were 25.13 ± 3.99 and 9.47 ± 1.97 hours (P < .05).
Jin et al 110 reported an RCT on cancer pain in patients with lung cancer (n = 87). The researchers assessed the effects of 2 combination therapies, Chinese herbal medicine plus radiation therapy and plus chemotherapy. Twenty-one patients in a treatment group (radiotherapy 60 Co 40-60 Gy 30 days plus an herbal injection, Yan-Shu, 20 mL intravenously once a day for 10 days) were compared with 19 patients in a control group receiving radiotherapy only. A treatment group of 26 patients received the same set of herbal injections plus 2 courses of chemotherapy (carboplatin 300 mg/m 2 , intravenously day 1; etoposide [VP16] 0.1, intravenously days 1-5) and were compared with 21 patients in a control group of chemotherapy only. In the radiotherapy study, the rate of pain relief in the treatment group was significantly better (80.95%) than in the control group (52.63%; P < .01). In the chemotherapy study, the rate of pain relief in the treatment group was also significantly better (65.38%) than in the control group (52.38%; P < .05).
Similar positive results were reported in the remainder of the articles. Seven RCTs 107,108,110,112-115 and 5 population-based consecutive case series [119] [120] [121] [122] [123] reported analgesic effects of intravenous injections of Yan-Shu. Two RCTs 109,116 and 1 case series 129 reported that an injection of Hua-Chan-Su reduced cancer pain. Two RCTs 117,118 and 3 population-based, consecutive case series 124-126 evaluated injections of another herbal extract, Kang-Lai-Te, on cancer pain. One RCT 111 and 2 population-based, consecutive case studies examined the effect of Shen-Fu injection, Elemenum emulsion, 127 and Ai-Di injections 128 on cancer pain, respectively.
Other Methods of Application
Three studies reported the use of other methods of application of Chinese herbal medicine: 1 RCT 130 and 1 population-based, consecutive case series 131 on inhalation, which is commonly used for pain management in nasopharyngeal carcinoma and carcinoma of the maxillary sinus, and an NRCT 132 on clysmata, which are used for gastrointestinal tract cancer pain. Guan et al (2006) 107 Zhuang et al Wang and Yang 130 reported an RCT with a treatment group (n = 50) that received inhalations of an acrid Chinese medicine (Herba Asari 细辛, Flos Caryophylli 丁香, Ligustici Rhizoma 川芎, Herba Menthae 薄荷, and Borneolum Syntheticum 冰片) 3 to 6 times a day for 3 weeks. The control group (n = 50) was treated with indomethacin (an NSAID) 25 mg orally 3 times a day for 3 weeks. The total rate of pain relief in the treatment group (72%) was significantly better than that of the control group (52%; P < .05). Onset of analgesic action took 23.17 ± 13.24 minutes in the treatment group versus 65.38 ± 24.86 minutes in the control group (P < .01). Analgesic duration was similar in both groups (4.00 ± 1.39 hours vs 4.61 ± 1.50 hours, respectively; P > .05). Niu 131 reported a population-based, consecutive case series in which 41 patients with moderate or severe pain were managed with Ai-Tong-Xin naristillae (2 drops every 6 hours for 7 days). The rate of pain relief was 73.13%, and the mean onset of analgesia was 4.20 ± 1.13 minutes.
In an NRCT reported by Liu, 132 30 patients with gastric cancer pain were treated with clysmata. The treatment group (n = 30) was given Chinese medicine (Corydalis Rhizoma 延胡索, Myrrh 没药, Rhizoma Cyperi 香附, and Excrementum Pteropi 五灵脂) clysmata, 80 mL per rectum 3 times a day. The control group (n = 15) was managed with atropine (an analgesic drug) and codeine phosphate (an opioid) clysmata (atropine 0.3 mg, codeine phosphate 30 mg, 0.9% normal saline [NS] 20 mL). The total rate of pain relief was significantly higher in the treatment group than in the control group (P < .05). Analgesic duration was 7.06 ± 0.93 hours in the treatment group, which was significantly longer than that in the control group (3.43 ± 1.26 hours; P < .05).
Adverse Reactions
Of the 115 articles reviewed, 60 articles 18, 20, [24] [25] [26] [27] [29] [30] [31] [32] 35, 38, 40, 41, 43, 45, 46, 50, 55, 56, [58] [59] [60] [61] [62] [63] 66, [68] [69] [70] [71] [72] 75, 78, 79, 82, 86, 87, 90, 91, [109] [110] [111] 113, 114, 116, 117, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] reported adverse reactions from the Chinese medicines used. Most reported symptoms were slight and brief and usually disappeared after the patients discontinued the medicine; in most cases, the patients did not need further medical intervention. Adverse effects were more often reported in the groups receiving conventional medicine than in herbal treatment groups.
Adverse reactions reported in studies of external applications [24] [25] [26] [27] [29] [30] [31] 50, 55, 56, 58 included skin rash, pruritus, blisters, and erubescences on the skin surface. There were a few reports 24 of nausea and vomiting following the use of external herbal applications. In studies of orally administered herbal medicine, [59] [60] [61] [62] [63] 66, [68] [69] [70] [71] [72] 86, 87, 90 adverse reactions included nausea, vomiting, dizziness, and drowsiness; a few patients reported constipation and diarrhea. Zhang 69 reported that a few patients had neuromuscular symptoms such as tremors in the muscles of the oral area and numbness of the tongue. Adverse reactions associated with intravenous infusion [109] [110] [111] 113, 116, 117, 122, 127 were low-grade fever, hidrosis and fatigue, dry mouth and skin rash, chest distress, dyspnea, and arrhythmia. Luo et al 113 reported that the side effects observed in the herbal treatment group included constipation, nausea, vomiting, urinary retention, abdominal distension, loss of appetite, headache, itch, and feeling flustered. However, the positive control group receiving analgesic drugs exhibited a higher rate of these symptoms.
Preclinical Research
Although cancer pain animal models have been available since 1994, 133 only a few published studies evaluate the efficacy and safety of Chinese herbal medicine on such models.
Tan et al 134 reported the effects of an injection of a purified extract of Chinese herbs, Kang-Lai-Te (KLT), on bone cancer pain in a rat model. The herbal extract was compared with morphine, celecoxib, and a 0.9% NS group and a sham cancer group (n = 6 per group). Paw withdrawal response and weight-bearing force in the KLT group were similar to those of the animals treated with the standard pain medicines, morphine and celecoxib (P > .05), but were significantly better than in the 0.9% NS group (P < .01). X-rays of the tibiae showed that tumor-induced bone destruction in both the KLT and the celecoxib groups was less severe than in the 0.9% NS and morphine groups.
Yu et al 135 evaluated the effects of an herbal tincture, Tong-Luo-San-Jie-Ding, on a rat model of tibia bone cancer pain. Voltaren emulsion was used on a control group. Tong-Luo-San-Jie-Ding administered for 7 days significantly prolonged paw withdrawal reaction time in rats with bone cancer pain compared with control (P < .05); at day 14, the effect of Tong-Luo-San-Jie-Ding was better than that of control (P < .05).
To the extent that the mechanisms of action of various Chinese herbal medicines on cancer pain have been explored, the research shows that their effects on pain may be mediated in peripheral tissues by prostaglandin, 5-hydroxytryptamine, nitric oxide, interleukin-1 and -8, and tumor necrosis factor and in the central nervous system by β-endorphin, which is a classic endogenous analgesic substance extensively distributed in the hypothalamus, brain, and spinal cord. These hormones and neurotransmitters may play important roles in the analgesic effects of Chinese herbal medicines, which appear to work on pain by increasing the secretion of these substances in the central nervous system. Further research 92, [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] on the mechanism of Chinese herbal medicine on cancer-related pain is warranted.
Discussion
Forty-one (35.65%) of the 115 studies reviewed are RCTs, most comparing the effects of Chinese herbal medicine with conventional analgesics and the others using placebo controls. 26, 66, 71 These trials suggest that (1) Chinese medicine may be effective for cancer pain, and its effects are similar to those of Western analgesics; (2) Chinese medicine may reduce the side effects of conventional analgesics, thus enhancing cancer patients' quality of life; and (3) the various methods of application-topical, oral, and intravenous-are suitable to treat a range of pain conditions found in cancer patients. It is, however, imperative to evaluate efficacy and safety rigorously, especially because Chinese herbal medicine is becoming increasingly popular in the West and elsewhere.
Of these studies, few are of high quality with adequate research design. For example, Chen et al 71 and Wei et al 66 reported randomized, double-blind, controlled, multicenter studies that evaluated the efficacy and safety of the analgesic mixture Gui-Shen and the capsule Tian-Chan for treating cancer pain, and both used placebo as control. Wei et al, 66 Wu et al, 63 and Luo et al 81 clearly described the inclusion criteria and exclusion criteria for patient enrollment. Luo et al 113 compared the rate of side effects in the treatment group with that of control.
However, most of the studies reviewed suffer from methodological flaws. Most were not randomized or controlled, suffered from inadequate blinding, had small sample sizes without adequate power calculation, had no clearly defined inclusion/exclusion criteria, and lacked sufficient follow-up time (some as little as 7 days). Because of the insufficient follow-up, it is impossible to determine whether the herbal medicines prolonged analgesia or only provided temporary pain relief. No patient consent procedures were reported, nor were human subject ethics committees mentioned. In the placebo-controlled and blinded studies, there were no reports on how the success of blinding was evaluated. Because most of these studies were designed and conducted by Chinese herbalists, the problem of bias is especially critical and should have been minimized by the rigorous scientific methods of proper randomization and concealment of patient allocation.
Other weaknesses of these studies may be related to inadequate reporting. Several reports of RCTs 24, 31, 63, 69 stated that participants were randomly assigned but gave no explanation as to how the allocation sequences were generated. None of these studies provided flow charts that clearly described the experimental procedures or the persons responsible for enrolling participants, assigning patients to treatment groups, or conducting outcome measurements, and only 60 studies reported adverse reactions that may be associated with the herbal medicines tested. Even in those studies reporting adverse effects, most did not specify how these effects were documented or followed up. The safety of Chinese herbal medicine is a vital concern for the public and practitioners. It is critical to document and report all adverse reactions and side effects in every treatment group, including controls, and particularly in those positive control groups receiving conventional Western medicine.
Other critical elements of Chinese herbal research are quality control and quality assurance of the herbal product. These are important not only to ensure that the herbal product is not contaminated with toxins such as heavy metals or pesticides but also to ensure batch-to-batch consistency so that future preparations of a given product will be of the same quality. The National Center for Complementary and Alternative Medicine has already provided guidance regarding herbal preparation quality in clinical research, which may be used as a rule (http://grants.nih.gov/grants/ guide/notice-files/NOT-AT-05-004.html).
It is worth noting that almost all the RCTs used a positive control using an approved, effective Western analgesic drug. This is probably because of ethical considerations. In China, it is still a common perception that the use of an inert placebo control is unethical. However, this is based on the assumption that the herbal medicine under investigation is effective. But what if it is not effective? Clinical studies are, after all, meant to determine whether the herbal medicine works, which raises another ethical concern if patients in treatment groups are not allowed to take analgesics. Furthermore, because patients and investigators are not blinded in positive drug-controlled studies, one cannot rule out the possibility of bias among investigators, placebo effect, expectation among patients, and that the positive effect of the herbal medicine may be a false positive. It would be a very serious ethical breach to put the herbal product on the market based on such "positive" results. Therefore, we recommend that the study design of future trials allow patients in both the herbal medicine treatment group and an inert placebo control group to take "rescue" analgesics to address this ethical concern. Any consumption of such analgesics should of course be documented and analyzed as an outcome measurement; the herbal treatment group would consume less INTEGRATIVE CANCER THERAPIES 6(3); 2007 analgesic if it works. This will address the ethical concern without compromising the science.
Conclusion
These studies suggest that Chinese herbal medicine may be useful for managing cancer pain, at least for short-term application. The products evaluated appear relatively safe with no serious adverse effects reported. There appears to be a widely applied and established practice and a significant body of practical clinical experience for the use of herbal preparations for the TCM treatment of cancer pain, which is not limited to oral application. Thus, a wide range of research opportunities may provide the possibility of improved care of cancer patients suffering from pain.
However, the research methods used in these studies are relatively poor, and the studies are not well reported. Because the strongest level of evidence should be obtained from well-designed and wellconducted clinical trials, further clinical studies on Chinese herbal medicine for cancer pain using rigorous scientific methods are warranted. Good research design and adequate reporting are clearly essential if researchers, reviewers, and clinicians are to reliably appraise and interpret results of such trials. 152 
